LSE:68CT

Novartis Leqvio shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…

3 months ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…

4 months ago